Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opus Genetics (IRD) Retained Earnings (2019 - 2026)

Opus Genetics has reported Retained Earnings over the past 13 years, most recently at -$254.1 million for Q1 2026.

  • Quarterly Retained Earnings fell 72.65% to -$254.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$254.1 million through Mar 2026, down 72.65% year-over-year, with the annual reading at -$188.6 million for FY2025, 35.68% down from the prior year.
  • Retained Earnings was -$254.1 million for Q1 2026 at Opus Genetics, down from -$188.6 million in the prior quarter.
  • Over five years, Retained Earnings peaked at -$71.5 million in Q4 2022 and troughed at -$254.1 million in Q1 2026.
  • The 5-year median for Retained Earnings is -$100.9 million (2022), against an average of -$119.7 million.
  • Year-over-year, Retained Earnings grew 27.27% in 2023 and then tumbled 72.65% in 2026.
  • A 5-year view of Retained Earnings shows it stood at -$71.5 million in 2022, then fell by 13.97% to -$81.5 million in 2023, then tumbled by 70.62% to -$139.0 million in 2024, then crashed by 35.68% to -$188.6 million in 2025, then plummeted by 34.75% to -$254.1 million in 2026.
  • Per Business Quant, the three most recent readings for IRD's Retained Earnings are -$254.1 million (Q1 2026), -$188.6 million (Q4 2025), and -$172.1 million (Q3 2025).